Search Results

Windtree Therapeutics, Inc., announced that on April 2, 2024 the Company entered into an asset purchase agreement with Varian Biopharmaceuticals, Inc. to acquire certain of its assets, including a proprietary atypical protein kinase C iota inhibitor.

iotaSciences, the Oxford-based leader in the rapidly growing field of single-cell handling solutions announced the appointment of Dr. Michael Lutz as CEO and Director for Iota Sciences Ltd.

Aurion Biotech, whose mission is to cure blindness by developing a differentiated platform of advanced therapies to treat ocular diseases, announced preliminary findings from its IOTA trial, conducted in November 2020 and in May of this year, at the Clínica Quesada in San Salvador, El Salvador.

The November layoffs are the second known workforce reduction this year for Marinus Pharmaceuticals, which previously announced disappointing Phase III results for ganaxolone in two clinical trials.

Astellas Pharma is building on a 2019 collaborative relationship and snapping up California-based iota Biosciences and that company’s bioelectronics technology in order to accelerate its Rx+ business.

New Linux Foundation Effort ‘Project Alvarium’, Will Utilize IOTA’s Open Source and Scalable Distributed Ledger Technology to Deliver Trusted Data At Scale

T2 Biosystems, Inc. (NASDAQ:TTOO), today announced that its T2SARS-CoV-2™ Panel—a molecular diagnostic test that detects SARS-CoV-2, the virus responsible for COVID-19 infections—is capable of detecting the Mu (B.1.621) and Iota (B.1.526) variants of the SARS-CoV-2 virus, which were recently confirmed to be present in the United States.